A DIGITAL HEALTH INFORMATION JOURNEY

“Empowering and equipping Europeans with health information
for active personal health management and adherence to treatment”
ABOUT US

The Gravitate Health is a public – private partnership with 45 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI2 Associated Partners.

Mission

The Gravitate Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life.

Vision

Engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level.

Ambition

To provide a key piece to advance this vision: the Gravitate Lens (G-lens®), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs.

0
.20
Project Launch
0
mo.
Duration
0
Mio Budget
0
Partners
ANNOUNCEMENT BOARD
JOIN

our Open E2E ePI Community, become a catalyst for innovation & change

FIND OUT

ENGAGE with us
ask questions, subscribe to ‘Under the Lens’ newsletter

FIND OUT
FOLLOW US

and share your feedback on LinkedIn 

FIND OUT

OUR LATEST news
500x280_Post-Final Conference2
500x280px_GravitateHealth__ePI-on-FHIR_PART_3
500x280px_GravitateHealth_Closing-1
Project Leads

Lorem Ipsum proin gravida nibh vel velit auctor aliquet. Aenean sollicitudin, lorem quis bibendum auctor, nisi elit consequatm proin gravida nibh vel ipsum, nec sagittis sem nibh id elit. Duis sed odio sit amet nibh vulputate cursus a sit amet mauris. Morbi accumsan ipsum velit. Nam nec tellus a odio tincidunt auctor a ornare odio. Sed non mauris vitae erat consequat.

Anne Moen
University of Oslo; Gravitate-Health Academic Coordinator
One of the longest lasting and important achievements in and with Gravitate-Health is that we were able to engage so many stakeholders, build and engage two different communities. The Gravitate-Health ePI Technology Community, which was oriented towards technology development tooling and standards, and as well as the Gravitate-Health Open End-to-End Collaborative Community where we emphasized also the need to focus on structuring, making sure that we drive the community towards G-lens ready ePIs.
Giovanna Ferrari
Pfizer; Gravitate-Health Project Lead

Our achievement with the longest lasting impact may well be the tangible steps we’ve taken to truly understand what is necessary to deliver a properly patient-centric electronic product information that can better serve the needs of patients and one, moreover, which can be firmly embedded in the digital healthcare information environment of the future

João Almeida
HL7 Europe; Gravitate-Health Product Owner

It has been great seeing Gravitate-Health apply HL7 FHIR ePI standards to connect medicine information with real world patient context, making information more actionable and relevant.

...Gravitate Health is an integrated digital health information project.

Gravitate Health services and the G-lens® will be developed and tested within the project, using an evaluation framework to test their ability to improve access to & understanding of health information, drive adherence and improve patient outcomes.

MILESTONES
G-lens® mock-ups and KPIs
100%
1st version of FOSPS architecture
100%
Concept validation of FOSPS platform and G-lens®
100%
Use case prioritizing for real world validation
100%
Gravitate Health FOSPS final version
100%
Gravitate Health Project Duration
99%
PARTNERS

45 partners from all over Europe and the US participate in the project, with 4 new partners acceding in the second semester of 2024.

Akershus Universitetssykehus
AstraZeneca AB
Bayer Aktiengesellschaft
Medicines Evaluation Board – MEB
Datapharm Limited
Datawizard SRL
Division of Clinical Informatics at Beth Israel Deaconess Medical Center
Eli Lilly and Company Limited
empirica Gesellschaft für Kommunikations-und Technologieforschung mbH
Global Health Connector (Connector)
F. Hoffmann – La Roche AG
Forum Europeen des Patients (EPF)
Grünenthal GmBH
Guardtime OÜ
HIMSS Europe GmBH
HL7 Europe
Karolinska Institutet
Københavns Universitet
MDSOL Europe Ltd (Medidata)
MINDVIEW Business Consulting & Research LTD
Norsk e-Helse AS
Norwegian Centre for eHealth Research
Novartis Pharma AG
PredictBy
Pfizer Limited (Project Lead)
Universitet i Oslo (Coordinator)
Serviços Partilhados do Ministério da Saúde, E.P.E.
Direktoratet for medisinske produkter – DMP (Norvegian Medical Products Agency – NoMA)
The European Institute for Innovation through Health Data [i-HD]
The Synergist
Trifork Public A/S
Trinity College Dublin
UCB Biopharma SRl
Università Cattolica del Sacro Cuore – EMH
Viatris
Universidad Politécnica de Madrid (UPM) – LifeSTech
Servicio Madrileño de Salud
University College Dublin (UCD)
Oslo University Hospital
Janssen
Fass
Pharmaca Health Intelligence Ltd
FELLESKATALOGEN
Medicin.dk
Agencia Española de Medicamentos y Productos Sanitarios
SURVEYS

Participate in our surveys for consumers / patients / HCPs…

Subscribe to our newsletter
Citizens
Policy and regulatory institutions
Researchers
Industry, SMEs / developers
Healthcare providers / professionals

You are welcome to contact us for any matter,
just submit the following form.

    Supported by a grant from IMI
    This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 945334. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA], and Datapharm Limited. The total budget is 19.4M€ for a project duration of 60 months.

    Disclaimer:
    Information on this website reflects Project owner’s views and neither IMI nor the European Union, EFPIA, or or Datapharm Limited are liable for any use that may be made of the information contained herein.